Stabilisation of disease as defined by food textures and/or reduced episodes of review score must be greater than the stable functional scores (ADLs) or aspiration qualifying score. quantitative muscle scores or MRC muscle assessment trial previous On review of a continuing authorisation period evidence of deterioration in one of these scores. Patient demonstrating stabilisation or improvement in muscle weakness as measured by MRC Sum (12) Score (greater than or equal to the previous review score). OR Patient demonstrating stabilisation or improvement in dysphagia as assessed by speech therapy, improved tolerance of food texture and/or reduced episodes of aspiration AND A off Ig therapy is planned or a valid reason is provided as to what a trial is not being planned or is contraindicated at this time.
Stabilisation of disease as defined by stable functional scores (ADLs) or quantitative muscle scores or MRC muscle assessment previous evidence of deterioration in one of these scores. food textures and/or reduced episodes of aspiration On review of a continuing authorisation period Patient demonstrating stabilisation or improvement in muscle weakness as measured by MRC Sum (12) Score (greater than or equal to the previous review score). OR Patient demonstrating stabilisation or improvement in dysphagia as assessed by speech therapy, improved tolerance of food texture and/or reduced episodes of aspiration AND A trial off Ig therapy is planned or a valid reason is provided as to what a trial is not being planned or is contraindicated at this time. review score must be greater than the qualifying score.
inflammatory-myopathies-polymyositis%28pm%29-dermatomyositis%28dm%29-and-necrotising-autoimmune-myopathy%28nam%29.DOCX